|
Heart disease is the #1 global killer and while cholesterol's precise role is debated, most agree LDL cholesterol - a.k.a. "bad cholesterol" - plays at least some role.
Which is why people spend ~$20 billion/year on statin drugs to lower LDL (note: statins are also hotly debated).
Welp…Eli Lilly may have just radically changed the landscape.
This week they published clinical data of a gene therapy called VERVE-102 that reduced LDL up to 62% after a single dose. Even wilder? The effect held for eighteen months.
VERVE-102 isn't a drug - it's a means of editing your genome to permanently turn off the liver gene responsible for high LDL levels.
And again, it's one. single. shot.
Some think this foretells the end of most heart disease - an astonishing possibility. Others warn about caveats to the study (e.g., small trial, no comparison group).
Either way, this is likely to change the world in a big way.
|
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.